FDA Orphan Drug Designation Granted to Oxaliplatin for the Treatment of Pancreatic Cancer June 2, 2026
FDA Accepts NDA with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST June 2, 2026
CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline May 21, 2026
Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan in Gastrointestinal Tumors May 21, 2026
FDA cleared IND for Ph 1/2 study of oral elraglusib in metastatic melanoma, NSCLC, colorectal, and pancreatic cancers May 12, 2026
Study initiated to evaluate Pidnarulex (CX-5461) + tislelizumab in pancreatic cancer, colorectal cancer, and melanoma May 12, 2026
FDA Commissioner’s National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma May 12, 2026
FDA Approves BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher May 12, 2026
Tovecimig Demonstrates Statistically Significant PFS Benefit but misses the OS benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer May 6, 2026
FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer May 6, 2026
Positive Ph 2a Data with Namodenoson in Pancreatic Cancer Reported; 35% of Patients Remain on Therapy, Including One Beyond 16 Months May 6, 2026
Ph 2/3 Clinical Trial Application submitted to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer May 6, 2026
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer April 28, 2026
FDA Accepts for Priority Review Supplemental BLA for Ziihera® (zanidatamab-hrii) Combo in 1L HER2+ Locally Advanced or Metastatic GEA April 28, 2026
Dose expansion in clinical study of spevatamig + chemo for treatment of biliary tract cancer April 28, 2026
First Pancreatic Cancer Patient in Europe treated with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial April 28, 2026
